BioPharmX has received approval from the Institutional Review Board (IRB) to begin a PRISM Phase ll trial to examine the safety and efficacy of BPX-04 for the treatment of papulopustular rosacea.

The trial will be based on data from the company’s open-label feasibility study that evaluated the tolerability of BPX-04 topical minocycline gel in subjects with papulopustular rosacea.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Based on the 12-week feasibility study, BioPharmX has selected the 1% minocycline concentration of BPX-04 gel for use in the PRISM trial.

The feasibility study enrolled 30 subjects with moderate-to-severe papulopustular rosacea.

During the study, the subjects received a once-daily administration of either 1%, 2%, or vehicle applied to the face.

“Dermatologists have long desired a new topical antibiotic option that minimises the risks of systemic side effects while not contributing to the bigger issue of systemic antibiotic resistance.”

All treatment arms were reported to be well tolerated and no serious adverse events were observed during the trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The results further demonstrated the patient-centric benefits of the BioPharmX HyantX delivery system underpinning BPX-04.

The trial’s principal investigator Dr Neal Bhatia said: “Optimising delivery to the source of the disease, while minimising the risks of oral antibiotics in patients with rosacea, has the potential to influence better prescribing options for dermatologists.

“Dermatologists have long desired a new topical antibiotic option that minimises the risks of systemic side effects while not contributing to the bigger issue of systemic antibiotic resistance.”

According to the National Rosacea Society, rosacea is a common disorder of the facial skin that affects around 16 million people in the US, many of whom do not even know they have the condition.

The disease is characterised by facial redness, pimples, bumpy breakouts, and thickening of the skin.